INTRODUCTION
Atrial fibrillation (AF) is the most common heart arrhythmia worldwide [1] . Worryingly, AF is related to higher rates of stroke and mortality [2] . Many risk scores and biological markers have been identified and developed to predict future AF events. Among the most frequently used and validated risk scores based on clinical parameters are CHADS2 [congestive heart failure, hypertension, age ≥ 75 years, diabetes, and stroke or transient ischemic attack (2 points) ] and CHA2DS2-VASc [cardiac failure or dysfunction, hypertension, age 65-74 (1 point) or ≥ 75 years (2 points), diabetes mellitus, and stroke, TIA or thromboembolism (2 points) -vascular disease, and sex category (female)] [3, 4] . In addition, biomarkers may significantly contribute to obtain additional information regarding the risk that could influence the management of AF. Therefore, there is also an increasing interest in determining whether biomarkers themselves or in combination with clinical risk scores enhances prognostic accuracy for thromboembolism and mortality in AF patients [5, 6] . A wide range of biomarkers have been evaluated as predictors and/or prognostics, such as cardiac troponin I and T, natriuretic peptides, D-dimer, CRP, galectin-3, growth differentiation factor-15, among others [1, 5, 7, 8] . The incorporation of biomarkers in the actually used risk scores seem to be helpful for early identifying AF patients at higher risk (i.e., enhanced risk for stroke, systemic embolic event or death), determining also their eligibility for anticoagulation and/or individualizing the most appropriate treatment strategy. Biomarkers are dynamic, and for that reason, they are also highly recommended to be included into management of patients with AF. Therefore, knowledge of new biomarkers related to AF may provide clinicians with more potential tools to quickly identify patients at higher risk of AF, attenuate its occurrence, improve its management, and decrease the risk of adverse events in patients with AF.
The search for hematological predictors of AF commenced in 1987 with the publication of a seminal study by Imataka et al [9] , who demonstrated that plasma volume and erythrocyte biology may be significantly perturbed in patients with AF. Ten years later, Takahashi et al [10] first showed that erythrocyte size was altered both before and after the onset of chronic AF, thus leading to way to subsequent research aimed to define whether high heterogeneity of erythrocytes volumes, conventionally known as anisocytosis, may have clinical significance in AF.
Anisocytosis, defined as the presence of red blood cells (RBCs) with a broad heterogeneity of size and volume in peripheral blood, can be reliably estimated by the vast majority of modern hematological analyzers using different techniques, which provide a similar final index called RBC distribution width (RDW) [11] . The RDW, which is not directly measured by the analyzers, but can be calculated as standard deviation (SD) of the mean corpuscular volume (MCV), and is usually expressed in absolute value (i.e., RDW-SD) or as the coefficient of variation [i.e., RDW-CV: (RDW-SD)/(MCV) × 100]. Albeit largely instrument-dependent, the reference range of RDW-CV is usually comprised between 11.5%-14.5% [12] . Increased RDW values, thus reflecting anisocytosis, may be due to many pathological conditions including congenital erythrocyte disorders (i.e., β-thalassemia, sickle cell disease, hereditary spherocytosis), anemia (e.g., due to iron, folate or vitamin B deficiencies), blood transfusions, some forms of hemolytic anemias, oxidative stress, inflammation and impaired renal function [13] [14] [15] . Since the measurement of RDW has now become a useful part in diagnostic and prognostic assessment of many cardiovascular disorders such as acute coronary syndrome (ACS), heart failure and venous thromboembolism [16, 17] , the aim of this critical review of the scientific literature is to investigate the potential clinical significance of measuring RDW in patients with, or at risk of, AF.
SEARCH STRATEGY
A systematic electronic search was carried out using the three well-recognized and widely accessed scientific databases (i.e., Medline interface PubMed, Web of Science and Scopus/EMBASE) [18] , with no date or language limits, to identify all articles which described the association between RDW and AF in epidemiological investigations involving human adult populations (cross-sectional, retrospective and prospective studies). The following keywords were used: "atrial fibrillation" AND "red blood cell distribution width" OR "RDW". The bibliographic references of selected items were also carefully checked for identifying additionally relevant documents. The title, abstract and full text of the articles were accurately reviewed by two authors (Lippi G and Cervellin G) , and potential disagreement for inclusion was eventually resolved by the opinion of the third author. Although no meta-analysis was specified before the electronic search, since it was already clear that the studies could not be combined due to large heterogeneity in sample size, setting, and endpoints, it was our aim to explore whether this approach would still be possible after analyzing the data of the included studies.
SEARCH RESULTS
The search strategy retrieved a total number of 70 documents after elimination of replicates among the three scientific search platforms. Thirty five studies ought to be excluded since they did not match our search criteria ( Figure 1 ). Data abstraction was hence conducted on a final number of 35 articles describing an epidemiological association between RDW and atrial fibrillation in adult populations, published between the years 2010 and 2019 (13 cross-sectional, 12 prospective and 10 retrospective studies) (Figure 1 ). It was finally decided that, as predictable, a metaanalysis was unfeasible due to large heterogeneity of the different studies (difference in nature, clinical settings, and endpoints, sample size from 49 to over 69000, no clear description of comorbidities in all studies, use of rather different RDW thresholds) ( Table 1) .
DESCRIPTION OF STUDIES OUTCOME
The first epidemiological investigation which could be identified in this critical literature review was published in 2010 by Horne and collaborators [19] . In this prospective investigation, based on the Intermountain Heart Collaborative Study, a total number of 3927 patients undergoing coronary angiography were evaluated after 1 year and 30 d, with the aim of defining the frequency of incident cardiovascular disorders and complications (including AF). When patients were classified according to quintiles of RDW, the frequency of incident AF steadily increased from the lowest up to the highest (i.e., from 2% to 14%) RDW quintiles. A highly significant trend towards increasing frequency of AF was consistently observed across RDW quintiles (P < 0.001).
Providência et al [20] carried out a cross-sectional study including 247 patients presenting with symptomatic AF to the emergency department, who were then subjected to transesophageal echocardiography for ruling out left atrial appendage thrombus. Overall, eft atrial appendage thrombus was evidenced in 21/247 (8.5%) of all AF patients, and its presence was found to be significantly more frequent in patients with RDW ≥ 15.0% than in those with lower RDW values (14.8% vs 5.4%; P = 0.013).
Liu et al [21] carried out another cross-sectional study including 133 patients with paroxysmal AF and 101 healthy controls. In multivariate logistic regression analysis, a RDW value > 12.55% was associated with a 63% enhanced risk of AF (odds ratio, 1.63; 95%CI: 1.01-2.61).
Ertaş et al [22] retrospectively studied 132 patients undergoing nonemergency coronary artery bypass graft (CABG) surgery. A RDW > 13.45% was associated with a nearly 1.5-fold increased risk of new-onset AF (hazard ratio 1.48; 95%CI: 1.07-2.06). The same team of authors published another cross-control study, in which RDW was measured in 126 patients with non-valvular AF (39 with stroke and 87 without) and in 126 healthy controls with no AF [23] . The value of RDW was found to be significantly higher in AF patients with (14.1% ± 1.7%) or without stroke (14.3% ± 1.8%) compared Kurt et al [24] , 2014 Cross-sectional 320 patients with AF Relationship with CHA2DS2-VASc score
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Jurin et al [52] , to the control population (13.2% ± 0.9%), but its value did not differ among AF patients with or without stroke (P > 0.05). Kurt et al [24] measured RDW in 320 patients with AF and found that those with a higher CHA2DS2-VASc score had also significantly higher RDW values than those with a lower CHA2DS2-VASc score (14.9% ± 2.7% vs 13.6% ± 1.7%; P < 0.001). A highly significant correlation could be observed between RDW and CHA2DS2-VASc score (r = 0.383; P < 0.001). In multivariate analysis, a RDW value > 14.05% was associated with a 25% higher risk (odds ratio, 1.25; 95%CI: 1.11-1.42) of having high CHA2DS2-VASc score (i.e., ≥ 2).
In an ensuing investigation, Güngör et al [25] studied 117 patients with AF and 60 healthy control subjects, concluding that RDW values were significantly higher in AF cases than in controls (13.4% vs 12.6%; P = 0.01). In multivariate regression analysis, a RDW > 12.9% was associated with a nearly 4-fold higher risk (odds ratio, 4.18; 95%CI: 2.15-8.15) of AF.
Adamsson Eryd et al [26] carried out a large prospective study including 27124 subjects free from AF at enrollment, who were followed-up for a mean period of 13.6 years. Subjects in the highest quartile of RDW had a 33% enhanced risk (hazard ratio, 1.33; 95%CI: 1.16-1.53) of developing AF on follow-up compared to those in the lowest quartile. Moreover, each 1 SD increase of RDW value was associated with a 8% higher risk (hazard ratio, 1.08; 95%CI: 1.04-1.12) of incident AF.
Sarikaya et al [27] studied 126 patients with hypertension (63 with AF and 63 without) and reported that RDW values were significantly higher in patients with AF than in those without (15.1% ± 1.6% vs 14.0% ± 1.1%; P = 0.001). In multivariate logistic regression analysis, a RDW value > 14.2% was found to be independently associated with 1.8-fold higher risk (odds ratio, 1.85; 95%CI: 1.22-2.79) of AF.
Gurses et al [28] measured RDW in 299 patients with paroxysmal or persistent AF undergoing cryoballoon-based ablation, and who were then followed-up for a mean period of 24 mo. A RDW value > 13.75% was independently associated with both early (hazard ratio, 6.39; 95%CI: 3.41-11.97) and late (hazard ratio, 1.88; 95%CI: 1.41-2.50) recurrence of AF, enhanced left atrial diameter (hazard ratio, 3.09; 95%CI: 1.81-5.27), as well as with duration of AF (hazard ratio, 1.04; 95%CI: 1.01-1.07).
Korantzopoulos et al [29] studied 109 patients undergoing elective cardiac surgery, who were then prospectively followed-up throughout hospitalization. In multivariate logistic regression analysis, a RDW > 13.35% was independently associated with a 46% higher risk (odds ratio, 1.46; 95%CI: 1.08-1.99) of developing postoperative AF during hospital stay.
Wan et al [30] carried out a prospective study including 300 patients with AF who were followed-up at a median period of 3.2 years. Patients in the fourth quartile of RDW values had a 2.7-fold higher risk (hazard ratio, 2.70; 95%CI: 1.35-5.83) of major adverse events (all-cause mortality, ACS, stroke and major hemorrhage) and a 3.8-fold higher risk (hazard ratio, 3.83; 95%CI: 1.53-9.58) of death during follow-up.
Lee et al [31] measured RDW values in 567 patients with newly diagnosed paroxysmal AF, who were followed-up for a median period of 4.8 years. In multivariate analysis, an increased RDW value (no indications provided on the cut-off used) was independently associated with 47% higher risk (hazard ratio, 1.47; 95%CI: 1.05-2.05) of new-onset stroke, 26% higher risk (hazard ratio, 1.26; 95%CI: 1.02-1.54) of composite outcome (mortality, new-onset stroke and hospitalization for heart failure), and 74% enhanced risk of bleeding (hazard ratio, 1.74; 95%CI: 1.28-2.36) throughout follow-up.
Zhao et al [32] retrospectively analyzed a local echocardiology database for identifying all AF patients who underwent transesophageal echocardiography before catheter ablation or electrical cardioversion. The final study population consisted of 90 AF patients, 24 of whom had evidence of left atrial thrombus (n = 11) or left atrial spontaneous echo contrast (n = 13). The mean RDW value was found to be significantly higher in patients with these two complications than in those without (13.0% ± 0.9% vs 12.6% ± 0.8%; P = 0.039).
Aksu et al [33] studied 49 patients with symptomatic paroxysmal AF who underwent cryoballoon ablation and were then followed-up for a mean period of 10 mo. Patients with AF recurrence on follow-up had significantly higher RDW values than those without (16.1% ± 1.4% vs 14.9% ± 0.5%; P = 0.033). Interestingly, the post-ablation RDW value remained almost unchanged in patents without recurrence of AF, but in those with AF recurrence the RDW significantly increased from 16.1% ± 1.4% to 16.3% ± 2.4% (P < 0.05).
In another study, Korantzopoulos et al [34] sinus syndrome (32 with AF), and found that a RDW value > 14.0% was independently associated with AF (odds ratio, 1.58; 95%CI: 1.06-2.85). Karataş et al [35] studied 621 patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention, and who were followed-up throughout hospitalization. Patients with RDW > 13.4% had a 55% higher risk (odds ratio, 1.55; 95%CI: 1.20-2.01) of developing new-onset AF until hospital discharge.
Yanagisawa et al [36] measured RDW in 757 patients undergoing radiofrequency catheter ablation for AF, who were then followed-up for a mean period of 22 mo. In multivariate linear regression analysis, a RDW value > 13.9% was associated with 20% higher risk (hazard ratio, 1.20; 95%CI: 1.01-1.40) of recurrent AF in patients with heart failure, whilst no significant association was found in those without heart failure. In patients with heart failure, a RDW value > 14.8% was also associated with 83% higher risk (hazard ratio, 1.83; 95%CI: 1.13-2.72) of developing major adverse events (allcause mortality, hospitalization for heart failure and cerebral ischemia) during followup.
Vizzardi et al [37] carried out a retrospective study including 232 patients with stable heart failure, whose clinical outcome was assessed 1 year after enrolment. In multivariate logistic regression analysis, a RDW value > 14.45% was independently associated with 3.9-fold enhanced risk (odds ratio, 3.89; 95%CI: 1.04-14.55) of cardiovascular death and/or hospitalization for heart failure in the first year after enrolment.
Geçmen et al [38] carried out a prospective study including 94 patients undergoing isolated on-pump CABG surgery, who were followed-up until discharge from the cardiovascular intensive care unit. In univariate analysis, higher RDW values were associated with a 41% higher risk (odds ratio, 1.41; 95%CI: 1.01-1.96) of postoperative AF during cardiovascular intensive care unit stay. The cut-off value of RDW was unavailable in the publication and the association between RDW and postoperative AF was not tested in multivariate analysis.
Zhang et al [39] measured RDW in 172 patients diagnosed with nonvalvular AF, who were followed up for 3 mo after catheter ablation. The overall number of bleeding events was found to be higher in patients with RDW values > 12.8% than in those with lower RDW values (11.8% vs 3.4%). Interestingly, the diagnostic efficiency (i.e., area under the receiver operating characteristics curve; AUC) for predicting bleeding occurrence was higher for RDW than for activated partial thromboplastin time (0.737 vs 0.558; P < 0.01).
Al-Kindi et al [40] used a large commercial database including electronic health Lippi G et al. Red blood cell distribution in atrial fibrillation records of many participating hospitals, with the aim of identifying patients aged 18 years or older with a diagnosis of HIV and who had at least one available RDW measurement. The search allowed the extraction of a total number of 46720 records (mean or median follow-up period for development of cardiovascular complications is unavailable in the article). In these HIV patients, a RDW value > 14.5% was independently associated with a 96% higher risk (odds ratio, 1.96; 95%CI: 1.64-2.33) of incident AF. Liu et al [41] studied 99 patients with AF, divided into two groups according to their CHADS2 and CHA2DS2-VASc scores. In multivariate logistic regression analysis, a RDW value > 12.55% was found to be significantly associated with higher (≥ 2) CHADS2 score (odds ratio, 2.18; 95CI%: 1.14-3.22), whilst a RDW value > 12.75% was found to be significantly associated with higher (≥ 2) CHA2DS2-VASc score (odds ratio, 5.75; 95%CI: 3.70-7.79).
Saliba et al [42] searched the electronic database for a large national health maintenance for identifying all patients diagnosed with AF in whom at least two RDW measurements were performed 1 year before study entry. Mortality data were retrospectively reviewed for up to 2 years after patients inclusion in the database. The electronic search identified a total of 69412 records. A RDW value > 14.5% was independently associated with a 49% increased risk (hazard ratio, 1.49; 95%CI, 1.43-1.55) of all-cause mortality during the follow-up period. More importantly, persistently increased RDW values at the two-time points were independently associated with an even higher risk of death during the same follow-up period (HR, 1.70; 95%CI: 1.61-1.79).
Kaya et al [43] analyzed the data of 619 AF patients undergoing transesophageal echocardiography examination before cardioversion or AF ablation. In multivariate regression analysis, a RDW value > 13.7% was associated with a 67% increased risk of left atrial stasis (odds ratio, 1.67; ).
Cha et al [44] carried out a retrospective study including 5082 patients with nonvalvular AF, who were followed-up for a mean period of 5.2 years. The RDW was measured several times during follow-up, allowing to identify nadir (i.e., the lowest), peak (i.e., the highest) and mean RDW values. Among the various RDW measures, a peak value ≥ 13.9% was independently associated with a 66% enhanced risk (odds ratio, 1.66; 95%CI: 1.41-1.96) of thromboembolic events, including ischemic stroke and systemic embolism.
Nam et al [45] carried out a cross-sectional study including 103 healthy control subjects and 117 patients with AF, 65 of whom with paroxysmal AF and 52 with persistent AF. Overall, no significant difference was found in mean RDW values between controls and AF cases (13.4% ± 1.6% vs 13.5% ± 0.8%; P = 0.343), whilst patients with persistent AF exhibited significantly higher mean RDW values than those with paroxysmal AF (13.9% ± 0.9% vs 13.3% ± 0.6%; P < 0.05).
Wasilewski et al [46] performed a sub-analysis of the COMMIT-HF (COnteMporary Modalities In Treatment of Heart Failure) registry, including 1734 patients with left ventricular ejection fraction ≤ 35% and without ACS at baseline, who were retrospectively investigated for a median period of 660 d. Patients in the highest RDW tertile had a more than double risk of developing AF on follow-up compared to those in the lowest tertile (44.1% vs 20.2%; P < 0.01).
Cerşit et al [47] investigated the association between RDW and AF in 50 patients with and without AF after an ACS. RDW was significantly higher in patients with AF than the control group (14.5% ± 2% vs 12.6% ± 1%, P < 0.001). A RDW of > 11.7% also predicted AF (sensitivity 56% and specificity of 64%; AUC = 0.637, P < 0.001).
Kılıcgedik et al [48] evaluated the RDW values in 358 patients who underwent CABG surgery [57 with post-surgery AF (PSAF) and 301 patients with non-PSAF]. Interestingly, RDW values were significantly higher in PSAF group. In multivariate analysis, RDW [OR: , P = 0.05] was found to be predictive for PSAF (68.4% sensitivity and 51.2% specificity; P = 0.001). Likewise, Ozsin et al [49] analyzed the RDW levels in 93 patients who underwent off-pump CABG surgery. 24 patients developed PSAF while 69 did not. RDW was significantly correlated with PSAF and was also found to be predictive for PSAF (79.2% sensitivity and 65.2% specificity; P = 0.001).
Pilling et al [50] analyzed the RDW levels in 240477 healthy volunteers (40 ± 70 at baseline) during a follow-up period of ≤ 9 years. Higher RDW levels (≥ 15% variation, n = 6050) was associated with AF (sHR 1.37: 1.21 to 1.55). RDW was also predictive of new-onset AF.
Han et al [51] investigated the effects of low altitude (3.5 m above the sea level) and high altitude (2260 m above the sea level) on RDW levels of 303 patients with nonvalvular AF. RDW levels were higher in AF than control individuals (P < 0.05) and higher in persistent AF than paroxysmal AF (P < 0.05) in both low and high altitudes. Moreover, RDW, was independently associated with AF in low altitude (RDW, OR: 1.687, 95%CI: 1.021-2.789; P < 0.05), whereas it was an independent predictor for AF (RDW, OR: 1.755, 95%CI: 1.179-2.613; P < 0.05) in high altitude.
Jurin et al [52] recruited 579 patients with AF, 412 with non-permanent AF and 167 with permanent AF, and followed-up the patients with non-permanent AF during a median time of 21 mo. The main endpoint was progression of non-permanent AF to permanent AF. 109 patients (26.6%) progressed to permanent AF. Moreover, increased RDW levels showed a significant independent association with the progression to permanent AF (HR 1.19, 95%CI: 1.03-1.39, P = 0.022).
Finally, Li et al [53] recently examined the relationship between RDW and AF in a general Chinese population (106998 subjects). The authors concluded that RDW was significantly related to a higher prevalence of AF; the OR (95%CI) of AF for increasing tertiles of RDW were 1.00 (reference), 1.08 (0.69, 1.67) , and 2.65 (1.75, 4.07) (P for trend < 0.0001), respectively.
Taken together, the results of these epidemiological studies, as well as results from two systematic reviews and meta-analysis recently published [54, 55] , are all virtually concordant to emphasize that an enhanced RDW value not only is a predictive factor and a marker of AF but its measurement may also be helpful for predicting the risk of developing many adverse complications in patients with AF, such as recurrence and duration of AF, hospitalization for heart failure, bleeding, left atrial thrombosis and stasis, thromboembolic events (including new-onset stroke) and mortality.
ANISOCYTOSIS IN ATRIAL FIBRILLATION: ACTIVE PLAYER OR BYSTANDER?
There are at least two biological explanations which can be brought for justifying the strong epidemiological association observed between anisocytosis and AF, either of which is plausible (Figure 2) .
The first and rather predictable scenario is that the same causative factors for AF may also impair erythropoiesis, and thereby the observation of an increased RDW value may only be a coincident epiphenomenon in AF [56] . For example, a high RDW value is commonplace in patients with recent blood transfusions or severe anemia [13] , and both RBC transfusion [57] and anemia [58] are associated with an excess incidence of AF, as consequence of onset of heart failure and impairment of renal function. Inflammation is probably the most frequent cause of anisocytosis [59] , but its contribution to the pathogenesis of AF is now almost unquestionable, since many inflammatory cytokines are known to impair atrial electrophysiology and structure [60] . Oxidative stress is another important inducer of anisocytosis [61] , whilst the oxidation of myofibrillar protein and cardiomyocyte membrane lipids is also a well-recognized mechanism leading to AF [62] . Finally, it is now clearly acknowledged that renal diseases may generate a kaleidoscope of inflammatory, neurohumoral, metabolic and hemodynamic stresses to the heart [63] , whilst impaired erythropoiesis and anisocytosis are also commonplace in patients with impaired renal function, mainly due to impaired erythropoietin production [13] (Figure 2 ). On the other hand, a support to the thesis that anisocytosis not only may be an innocent bystander in AF, but may also trigger, or contribute to worsening, AF has emerged from a discrete number of studies. Hirayama et al showed that the onset of arrhythmias is strongly associated with reduced erythrocyte deformability [64] , which is a conventional hallmark of anisocytic erythrocytes [65] . A large variation of erythrocytes volume is also associated with a greater cholesterol content in the RBC membrane, which can then be directly transferred to atherosclerotic plaques enriched in erythrocytes [66, 67] , thus finally promoting atherogenesis and ultimately predisposing to cardiac arrhythmias, since AF atherosclerosis and AF are now considered two strictly intertwined disorders [68] . Finally, the presence of anisocytic erythrocytes has also been involved in the mechanisms underlying adverse cardiac remodeling [69] , thus leading to atrial fibrosis and predisposing the patients to a higher risk of developing AF [70] .
CONCLUSION
The value of the RDW can be automatically generated, along with the other parameters of the complete blood cell count, by the majority of modern hematological analyzers. It can therefore be considered an easier, faster and less expensive test compared to other potentially useful biomarkers in AF [1] . Regardless of the fact that anisocytosis may be a simple bystander or an active player in the pathogenesis of AF and of its life-threatening complications, the current epidemiological evidence convincingly suggests that routine measurement of RDW may provide valuable clinical information for diagnosis and management of AF, alone or combined with traditional risk scores such as CHADS2 and CHA2DS2-VASc [71] . In particular, the strong and often independent association observed between high RDW values and unfavorable outcomes (e.g., recurrence of AF, heart failure, bleeding, thromboembolic events and death) ( Table 1) , would lead us to conclude that AF patients with RDW values exceeding the local reference range may be more aggressively investigated and managed, in order to identify and reduce the impact of possible underlying disorders causing both anisocytosis and AF (Figure 2) , and also for preventing the possible risk of adverse events potentially attributable to anisocytosis. Additional studies are then advised to define whether the inclusion of RDW within conventional risks scores may be effective in providing more accurate risk stratification in AF.
